TAK 418

Drug Profile

TAK 418

Alternative Names: TAK418

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn genetic disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inborn genetic disorders

Most Recent Events

  • 15 May 2018 Takeda initiates enrolment in a phase I trial in healthy volunteers in USA (NCT03501069)
  • 12 May 2018 Takeda completes a phase I trial in Inborn genetic disorders (In volunteers) in USA (PO) (NCT03228433)
  • 26 Apr 2018 TAK 418 receives Orphan Drug status for Inborn genetic disorders (Kabuki syndrome) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top